Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.

@article{Santantonio2014AcuteHC,
  title={Acute hepatitis C: a 24-week course of pegylated interferon α-2b versus a 12-week course of pegylated interferon α-2b alone or with ribavirin.},
  author={Teresa Santantonio and Massimo Fasano and Evangelista Sagnelli and Paolo Tundo and Sergio Babudieri and Paolo Fabris and Mario Toti and Giovanni di Perri and Nicoletta Marino and Eligio Pizzigallo and Gioacchino Angarano},
  journal={Hepatology},
  year={2014},
  volume={59 6},
  pages={2101-9}
}
UNLABELLED Therapy of acute hepatitis C (AHC) has not yet been standardized and several issues are still unresolved. This open, randomized, multicenter trial aimed to assess the efficacy and safety of a 24-week course of pegylated IFN (Peg-IFN) alpha-2b versus a 12-week course of Peg-IFN alpha-2b alone or with ribavirin (RBV) in AHC patients. One hundred and thirty HCV acutely infected patients who did not spontaneously resolve by week 12 after onset were consecutively enrolled and randomized… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
15 Citations
17 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Early versus delayed treatment of acute hepatitis C: final results of the randomized controlled German HEP-NET acute HCV-III Study

  • K Deterding, N Gruners, P Buggisch, J Wiegand, P Galles, U Spengler
  • Lancet Infect Dis 2013;13:497-506. HEPATOLOGY,
  • 2014

Similar Papers

Loading similar papers…